LUCD Stock — Lucid Diagnostics Inc

Lucid Diagnostics Inc (LUCD)

Updated October 16, 2026.

LUCD is a Stock. Total return is -95.9% over the past 5 years, 180.3 points behind SPY at 84.4%.

Lucid Diagnostics is a commercial-stage medical diagnostics company focused on early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, primarily through its EsoGuard Esophageal DNA Test and EsoCheck cell collection device. As an early-stage diagnostics developer, the company does not currently have a distribution history. This security may appeal to investors seeking exposure to medical technology innovation, though investors should be aware of the risks associated with commercial-stage medical device companies.

LUCD performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.9% over the past 5 years, 180.3 points behind SPY at 84.4%. Over the past year its total return — price change plus distributions reinvested — is -61.1%. Its deepest 1-year drawdown was 67.5%.

LUCD key facts

Asset type

Stock

Asset class

Equity

Inception date

10/14/2021

Distribution frequency

None

Last close

$0.48 (as of 2026-10-16)

Market cap

$91,273,493

Average volume

2334977.0

Beta

1.124

Payout ratio

0.0%

EPS

$-0.44

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LUCD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 67.5%.

Who may consider LUCD — and who may not

It is a weaker fit for investors who need monthly cash flow (LUCD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LUCD

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions